Insider Selling: Twist Bioscience Co. (NASDAQ:TWST) CFO Sells 6,620 Shares of Stock

Twist Bioscience Co. (NASDAQ:TWSTGet Rating) CFO James M. Thorburn sold 6,620 shares of the business’s stock in a transaction on Thursday, April 14th. The stock was sold at an average price of $42.85, for a total value of $283,667.00. Following the sale, the chief financial officer now owns 46,688 shares in the company, valued at approximately $2,000,580.80. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

TWST traded down $1.87 during midday trading on Monday, hitting $40.72. 489,294 shares of the company were exchanged, compared to its average volume of 904,256. Twist Bioscience Co. has a 1-year low of $38.08 and a 1-year high of $144.14. The firm’s 50 day moving average price is $50.50 and its 200-day moving average price is $76.36.

Twist Bioscience (NASDAQ:TWSTGet Rating) last announced its quarterly earnings data on Friday, February 4th. The company reported ($0.91) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.08) by $0.17. The company had revenue of $42.00 million for the quarter, compared to the consensus estimate of $38.22 million. Twist Bioscience had a negative return on equity of 27.10% and a negative net margin of 112.70%. The firm’s revenue was up 48.9% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.72) EPS. Equities research analysts predict that Twist Bioscience Co. will post -4.97 EPS for the current fiscal year.

Several large investors have recently made changes to their positions in TWST. Commonwealth Equity Services LLC lifted its stake in shares of Twist Bioscience by 3.2% in the 3rd quarter. Commonwealth Equity Services LLC now owns 4,368 shares of the company’s stock valued at $467,000 after purchasing an additional 137 shares during the period. SG Americas Securities LLC raised its stake in Twist Bioscience by 62.6% during the 3rd quarter. SG Americas Securities LLC now owns 18,373 shares of the company’s stock worth $1,965,000 after buying an additional 7,073 shares during the period. Perigon Wealth Management LLC raised its stake in Twist Bioscience by 5.6% during the 3rd quarter. Perigon Wealth Management LLC now owns 3,117 shares of the company’s stock worth $333,000 after buying an additional 166 shares during the period. Victory Capital Management Inc. raised its stake in Twist Bioscience by 10.8% during the 3rd quarter. Victory Capital Management Inc. now owns 551,362 shares of the company’s stock worth $58,979,000 after buying an additional 53,644 shares during the period. Finally, Tygh Capital Management Inc. acquired a new position in Twist Bioscience during the 3rd quarter worth approximately $2,992,000. 98.81% of the stock is currently owned by institutional investors.

A number of equities research analysts recently weighed in on TWST shares. The Goldman Sachs Group reduced their price objective on Twist Bioscience from $105.00 to $55.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 13th. Barclays reduced their price objective on Twist Bioscience from $130.00 to $75.00 and set an “overweight” rating on the stock in a research report on Monday, February 7th. Robert W. Baird reduced their price objective on Twist Bioscience from $113.00 to $70.00 in a research report on Monday, February 7th. SVB Leerink cut their target price on Twist Bioscience from $110.00 to $70.00 and set a “market perform” rating on the stock in a report on Monday, February 7th. Finally, Zacks Investment Research raised Twist Bioscience from a “sell” rating to a “hold” rating in a report on Thursday, March 10th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $67.50.

Twist Bioscience Company Profile (Get Rating)

Twist Bioscience Corp. develops proprietary semiconductor-based synthetic DNA manufacturing process. It produces synthetic biology tools such as genes, oligo pools, variant libraries, DNA data storage and NGS. The firm also produces agriculture production as well as new applications such as in vivo diagnostics, biodetection and data storage.

Further Reading

Insider Buying and Selling by Quarter for Twist Bioscience (NASDAQ:TWST)

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.